HaemMetabolome will provide research training in the molecular mechanisms underlying the pathogenesis of several acute haematological malignancies (Acute Myeloid Leukaemia (AML) and Chronic Myeloid Leukaemia (CML) and multiple myeloma). Resistance to existing therapies is frequently observed for these diseases, and they remain incurable for the majority of cases.
The aim of HaemMetabolome is to take the next steps to understand the cell biological consequences of the genetic alterations that occur in the cells of these cancers, and understand how these can be used to improve treatment options. As these haematological malignancies are multi-factorial diseases, HaemMetabolome will develop the integration of biomedical multi-omics data and computational modelling systems with the aim to understand the metabolic regulation in haematological cancers. Systems biomedicine will be used to build genome-scale transcriptional models that explain the deregulated metabolic pathways relevant for the development of haematological cancers, and to help to identify biomarkers and new drug targets for patient-devived samples.
Next Meeting is 11th to 13th July … See here
